What Is CJC-1295 DAC? Benefits, Research & Safety

CJC-1295 DAC was developed by ConjuChem Biotechnologies, a Canadian biopharmaceutical company specialising in long-acting peptide therapeutics through their proprietary DAC technology platform. The technology was designed to overcome the fundamental pharmacokinetic limitation of native peptide hormones — their extremely short half-lives in circulation. The development built upon earlier work characterising modified GRF(1-29) analogues with enhanced DPP-IV resistance. ConjuChem's innovation was the addition of the Drug Affinity Complex, which enabled in vivo albumin binding and dramatic half-life extension without compromising receptor binding affinity. Phase I clinical trials were conducted in the early 2000s, demonstrating that a single subcutaneous injection could sustain elevated GH and IGF-1 levels for up to two weeks. Phase II trials followed, examining the compound in growth hormone deficiency and HIV-associated lipodystrophy. In 2006, a clinical trial participant experienced a serious adverse event (cardiac event), which led to a temporary clinical hold. Although investigators determined the event was unrelated to CJC-1295 DAC, the programme faced challenges, and ConjuChem ultimately discontinued development. Despite the cessation of formal pharmaceutical development, CJC-1295 DAC has remained widely discussed in research and biohacking communities, particularly in comparison to the non-DAC version (Mod GRF 1-29 or CJC-1295 without DAC), which requires more frequent dosing but offers pulsatile GH release patterns more closely mimicking natural physiology.